|
Michael Hayden, CM OBC FRSC is a Killam professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine, Hayden is best known for his research in Huntington disease. He is the founder and director of the Centre for Molecular Medicine and Therapeutics in Vancouver, Canada; a genetic research centre within UBC’s Faculty of Medicine and affiliated with the Child & Family Research Institute and the BC Children's Hospital Foundation. He is also the Program Director of the Translational Laboratory in Genetic Medicine in Singapore, and was recently appointed as the President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries
Hayden is the most cited author in the world for HD and ABCA1. In 2010 he was awarded Member of the Order of Canada, following his receipt of the Order of British Columbia in 2009. Hayden received the Canada Gairdner Foundation Wightman Award in 2011, and in 2008 received recognition from the Canadian Institutes of Health Research as Canada's Health Researcher of the Year: CIHR Michael Smith Prizes in Health Research. In addition to his academic work, Hayden is also the founder of three biotechnology companies, NeuroVir, Xenon Genetics Inc. and Aspreva Pharmaceuticals. He is the Chief Scientific Director of Xenon.
|
